

Right Ventricular Outflow Tract Arrhythmias: Benign Or Early Stage Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia?

GSergio Conti, MD¹, Laura Cipolletta, MD¹, Vittoria Marino, MD¹, Martina Zucchetti, MD¹, Eleonora Russo, MD¹, Francesca Pizzamiglio, MD¹, Ghaliyah Al-Mohani, MD¹, Salvatore Pala, BE¹, Valentina Catto, BE, PhD¹, Luigi Di Biase, MD, PhD^{2,3,4,5}, Andrea Natale, MD^{2,6,7,8,9}, Claudio Tondo, MD, PhD, FESC¹, Corrado Carbuicchio, MD¹

¹Cardiac Arrhythmia Research Centre, Centro Cardiologico Monzino IRCCS, Milan, Italy. ²Texas Cardiac Arrhythmia Institute at St David's Medical Centre, Austin, TX, USA. ³Albert Einstein College of Medicine at Montefiore Hospital, New York, USA. ⁴Cardiology Department, University of Foggia, Foggia, Italy. ⁵Department of Biomedical Engineering, University of Texas, Austin, USA. ⁶Division of Cardiology, Stanford University, CA, USA. ⁷Case Western Reserve University, Cleveland, OH, USA. ⁸EP Services, California Pacific Medical Center, San Francisco, CA, USA. ⁹Interventional Electrophysiology, Scripps Clinic, San Diego, CA, USA.

Abstract

Ventricular arrhythmias (VAs) arising from the right ventricular outflow tract (RVOT) are a common and heterogeneous entity. Idiopathic right ventricular arrhythmias (IdioVAs) are generally benign, with excellent ablation outcomes and long-term arrhythmia-free survival, and must be distinguished from other conditions associated with VAs arising from the right ventricle: the differential diagnosis with arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is therefore crucial because VAs are one of the most important causes of sudden cardiac death (SCD) in young individuals even with early stage of the disease. Radiofrequency catheter ablation (RFCA) is a current option for the treatment of VAs but important differences must be considered in terms of indication, purposes and procedural strategies in the treatment of the two conditions. In this review, we comprehensively discuss clinical and electrophysiological features, diagnostic and therapeutic techniques in a compared analysis of these two entities.

Introduction

The right ventricular outflow tract (RVOT) is the most common origin of non-ischemic ventricular arrhythmias (VAs). RVOT VAs - including premature ventricular contractions (PVCs) and non-sustained or sustained ventricular tachycardia (VT) - are the expression of two different entities, both in terms of natural history and in terms of therapeutic management: idiopathic right ventricular arrhythmias (IdioVAs) and arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D).^{1,2}

Key Words:

Right Ventricular Outflow Tract, Idiopathic Ventricular Arrhythmias, Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia, Three-Dimensional Electroanatomical Mapping, Cardiac Magnetic Resonance Imaging, Catheter Ablation.

Disclosures:

None.

Corresponding Author:

Corrado Carbuicchio, MD
Cardiac Arrhythmia Research Centre,
Centro Cardiologico Monzino IRCCS
Via Carlo Parea 4, 20138, Milan, Italy.

IdioVAs is a benign condition that occurs in young adults without structural heart disease, traditionally considered a primary electrical disease, responsive to medical and ablative therapy.^{3,4} ARVC/D is an autosomal dominant genetically determined heart muscle disorder characterized by pathological fibro-fatty replacement of the right ventricular (RV) myocardium, that leads to VAs, RV dysfunction and sudden cardiac death (SCD).⁵⁻⁷ In the early stage of the disease, structural changes may be absent or subtle, progressively affecting localized areas of the RV, typically the inflow tract, outflow tract, or apex of the RV, the so-called "triangle of dysplasia".⁸ However, the subsequent involvement of other regions of the RV is common.⁹ Whilst in the past the involvement of the left ventricle (LV) was considered an expression of the final stage of the disease, known as "biventricular failure phase", it is currently recognized that ARVC/D can present with isolated or predominant involvement of LV since the early stages.¹⁰ Clinical and genetic characterization of families demonstrated 3 different patterns of ARVC/D: classic pattern with predominant RV disease; left dominant pattern, with early and prominent LV disease; bi-ventricular pattern, with synchronous involvement of both ventricles.¹¹ The diagnosis of ARVC/D relies on the demonstration of structural, functional, and electrophysiological abnormalities, as defined by the 2010 modified Task Force criteria

Table 1:

Revised Task Force (TF) criteria of 2010.¹²

Global or regional dysfunction and structural alterations

Major Criteria

- 2D echo Regional RV akinesia, dyskinesia, or aneurysm and 1 of the following (end diastole):

PLAX RVOT ≥ 32 mm (corrected [PLAX/BSA] ≥ 19 mm/m²)

PSAX RVOT ≥ 36 mm (corrected [PSAX/BSA] ≥ 21 mm/m²)

or fractional area change $\leq 33\%$

- MRI Regional RV akinesia or dyskinesia or dyssynchronous RV contraction and 1 of the following:

Ratio of RVEDV to BSA ≥ 110 mL/m² (male) or ≥ 100 mL/m² (female)

or RV ejection fraction $\leq 40\%$

- RV angiography Regional RV akinesia, dyskinesia, or aneurysm

Minor Criteria

- 2D echo Regional RV akinesia or dyskinesia and 1 of the following (end diastole):

PLAX RVOT ≥ 29 to < 32 mm (corrected [PLAX/BSA] ≥ 16 to < 19 mm/m²)

PSAX RVOT ≥ 32 to < 36 mm (corrected [PSAX/BSA] ≥ 18 to < 21 mm/m²)

or fractional area change > 33 to $\leq 40\%$

- MRI Regional RV akinesia or dyskinesia or dyssynchronous RV contraction and 1 of the following:

Ratio of RVEDV to BSA ≥ 100 to < 110 mL/m² (male) or ≥ 90 to < 100 mL/m² (female)

or RV ejection fraction > 40 to $\leq 45\%$

Tissue characterization of wall

Major Criteria

Residual myocytes $< 60\%$ by morphometric analysis (or $< 50\%$ if estimated), with fibrous replacement of the RV free wall myocardium in ≥ 1 sample, with or without fatty replacement of tissue on EMB

Minor Criteria

Residual myocytes 60% to 75% by morphometric analysis (or 50% to 65% if estimated), with fibrous replacement of the RV free wall myocardium in ≥ 1 sample, with or without fatty replacement of tissue on EMB

Repolarization abnormalities

Major Criteria

Inverted T waves in right precordial leads (V1, V2, and V3) or beyond in individuals > 14 years of age (in the absence of complete RBBB QRS ≥ 120 ms)

Minor Criteria

Inverted T waves in leads V1 and V2 in individuals > 14 years of age (in the absence of complete RBBB) or in V4, V5, or V6

Inverted T waves in leads V1, V2, V3, and V4 in individuals > 14 years of age in the presence of complete RBBB

Depolarization/conduction abnormalities

Major Criteria

Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the T wave) in the right precordial leads (V1 to V3)

Minor Criteria

Late potentials by SAECG in ≥ 1 of 3 parameters in the absence of a QRS duration of ≥ 110 ms on the standard ECG

Filtered QRS duration (fQRS) ≥ 114 ms

Duration of terminal QRS < 40 μ V (low-amplitude signal duration) ≥ 38 ms

Root-mean-square voltage of terminal 40 ms ≤ 20 μ V

Terminal activation duration of QRS ≥ 55 ms measured from the nadir of the S wave to the end of the QRS, including R', in V1, V2, or V3, in the absence of complete RBBB

Arrhythmias

Major Criteria

Non-sustained or sustained VT of LBBB morphology with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL)

Minor Criteria

Non-sustained or sustained VT of RV outflow configuration, LBBB morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown axis)

> 500 ventricular extrasystoles per 24 hours (Holter)

Family History

Major Criteria

ARVC/D confirmed in a first-degree relative who meets current TF criteria

ARVC/D confirmed pathologically at autopsy or surgery in a first-degree relative

Identification of a pathogenic mutation categorized as associated or probably associated with ARVC/D in the patient under evaluation

Minor Criteria

History of ARVC/D in a first-degree relative in whom it is not possible or practical to determine whether the family member meets current TF criteria

Premature SCD (< 35 years of age) due to suspected ARVC/D in a first-degree relative

ARVC/D confirmed pathologically or by current TF criteria in a second-degree relative

RV = right ventricle, PLAX = parasternal long-axis, RVOT = right ventricular outflow tract, BSA = body surface area, PSAX = parasternal short axis, RVEDV = right ventricular end-diastolic volume, EMB = endomyocardial biopsy, RBBB = right bundle-branch block, SAECG = signal-averaged ECG, LBBB = left bundle-branch block, SCD = sudden cardiac death

adapted to improve diagnostic sensitivity.¹²

Radiofrequency catheter ablation (RFCA) is a highly effective treatment for symptomatic patients with IdioVAs, whilst the role of ablation in ARVC/D is not definitively curative. As such, differentiating between the two conditions is essential because

different procedural endpoints should be defined and different ablation strategies are required.¹³⁻¹⁵

Electrophysiological Properties Of The Embryonic Outflow Tract Related To Ventricular Arrhythmias In Adults

Anatomically, four portions of RVOT are described: rightward, also

Table 2:

Outflow tract VAs origin based on QRS pattern. ECG differentiation of a RVOT from a LVOT origin VAs is based on the R/S precordial transition.³²⁻³³

| Right ventricle | BBB | Axis | Precordial transition | V1 | V6 | other |
|-----------------|--------|----------|-----------------------|------------------------|----|--|
| RVOT septal | LBBB | Inferior | ≤ V3 | rS | R | (-) polarity of lead I in anterior and leftward location; (+) polarity in posterior and rightward location; multiphasic polarity in midway location. |
| RVOT free-wall | LBBB | Inferior | ≥ V3 | rS | R | (-) polarity of lead I in anterior and leftward location; (+) polarity in posterior and rightward location; multiphasic polarity in midway location. Notching in lead II, III and aVF. |
| LCC | LBBB | Inferior | ≤ V2 | QS/QR | R | |
| RCC | LBBB | Inferior | ≥ V3 | Multiphasic "M" or "W" | R | |
| AMC | "RBBB" | Inferior | ≤ V3 | qR | R | |

LBBB = left bundle branch block; LCC = left coronary cusp; RCC = right coronary cusp; AMC = aorto-mitral continuity.

called free wall, anterior, leftward, and posterior. The myocardium is relatively thin in the rightward, anterior, and leftward portions of the RVOT, whilst the posterior infundibular part is the thickest¹⁶ (figure 1). In the developing embryonic heart, the presence of "transitional zones", with slow conducting properties, seems to be related to the presumptive cardiac conduction system.¹⁷ One of these transitional zones is found in the myocardial outflow tract. Several markers related to the developing cardiac conduction system have been described in these zones,¹⁸ including the Hyperpolarization-activated cyclic nucleotide-gated channel 4 (HCN4), that is responsible for the current in the sino-atrial node (If).¹⁹ The expression of HCN4 among other markers (such as CCS-lacZ and MinK-lacZ^{20,21}), in RVOT of the developing heart may explain the occurrence of arrhythmias in the adult heart. Re-expression of an embryonic phenotype, or embryonic remnants of tissue may provide the arrhythmogenic potential of this area.²²

Clinical Presentation And ECG Of Ventricular Arrhythmias In Patients With IdioVAs And ARVC/D

Clinical presentation of IdioVAs typically includes palpitations, dizziness, related to frequent PVCs or non-sustained VT. Less frequently, physical exercise or emotional stress can lead to sustained VT that may be occasionally the cause for syncope. On the other hand, clinical presentation of ARVC/D may be variable: palpitations, but also syncope, cardiac arrest or SCD have been reported. Traditionally, 3 different phases have been distinguished. In the early "concealed phase", patients are commonly asymptomatic, with minor VAs and subtle RV structural changes. However, risk of SCD is reported particularly during exercise.⁵ In the second phase, "overt electrical phase", patients present symptomatic VAs and morphological RV abnormalities detected by imaging. Finally, the third phase is the "end-stage-disease", often indistinguishable from dilated cardiomyopathy.²³

Several ECG markers related to ARVC/D have been described.²⁴⁻²⁹ According to the Revised Task Force criteria, summarized in Table 1, evidence of negative precordial T-wave in V1-V3 or beyond and epsilon wave in V1-V3 on sinus rhythm are major criteria.¹²

Regarding presentation with VAs, the typical inferior axis / left bundle branch block (LBBB) pattern is common in more than 90% of IdioVAs patients. Differently, ARVC/D patients present with inferior axis as well as intermediate axis or superior axis VAs.³⁰ Recently, Hoffmayer et al. compared ARVC/D and IdioVAs patients in a population presenting with the same inferior axis / LBBB ECG morphology, finding several distinguishing criteria between the two conditions. With regard to the diagnosis of ARVC/D, QRS duration ≥ 120 ms in lead I was highly sensitive (88%), whereas a "notching" on QRS upstroke (88%), multiple QRS notching in different leads

(88%), earliest QRS onset in V1 (90%), late (V5; 90%) and very late (V6; 100%) precordial transition were all highly specific criteria.³¹

For clinical purposes, ECG characteristics of different sites of RVOT and the left ventricular outflow tract (LVOT) VAs are given in Table 2.^{32,33}

In the Revised Task Force criteria, Signal Averaged Electrocardiography (SAECG) is a minor criterion of ARVC/D.¹² However, O'Donnell and coworkers found that late potentials (LPs) on the SAECG were not present in any patient with RVOT tachycardia but were present in 78% of the patients with ARVC/D.³⁴ Moreover, in a recent non-invasive ECG study, the SAECG parameters and the frequency components recorded from the wavelet-transformed ECG were compared between three different groups: IdioVAs, ARVC/D and Brugada syndrome. Focusing on the first two entities, LPs were positive in all of ARVC/D patients whilst were negative in all of IdioVAs patients and high-frequency components (80-150 Hz) were developed in ARVC/D but not in IdioVAs.³⁵

Electrophysiological Differences Between IdioVAs And Ventricular Arrhythmias In ARVC/D

Taking into account the different underlying substrate of the two entities, electrophysiological findings help to differentiate IdioVAs from VAs in the setting of ARVC/D.

Different groups compared electrophysiological findings in patients with IdioVAs and ARVC/D reporting similar results.^{30,34} IdioVAs are due to cyclic AMP mediated triggered activity. Thus, it is a focal form of tachycardia, frequently presenting in form of non-sustained arrhythmias, sensitive to catecholamine infusion (i.e. epinephrine, phenylephrine or isoproterenol) and burst stimulation; for the same reason IdioVAs are monomorphic with the common inferior axis – LBBB morphology and present a presystolic high amplitude local electrogram.^{36,37}

VAs in context of ARVC/D are the expression of slow conduction areas within the diseased myocardium that allow continuous electrical activity, fragmented diastolic potentials (figure 2) in an expanded area, creating a circuit pathway. For this reason, programmed ventricular stimulation is more effective to induce VT in ARVC/D patients compared with IdioVAs.^{38,39} Moreover, the evidence of different reentry pathways justifies the inducibility of multiple VT morphologies that may be common in ARVC/D patients.

Imaging - Cardiac Magnetic Resonance

Cardiac magnetic resonance (CMR) imaging is increasingly used as a standard technique for imaging of RV structure and function. Indeed, CMR is the most reliable modality available for the quantification of ventricular size and volume and for the detection of RV morphological abnormalities due to its capacity to perform tissue characterization.




Figure 1:

RVOT can be thought of as a cylinder that wraps around LVOT. RVOT courses anterior to the LVOT, from a rightward inferior to a leftward superior direction, such that the pulmonary valve lies to the left and anteriorly to the aortic valve. The pulmonary annulus is cephalad to the aortic annulus thus the structure immediately anterior to the aortic valve, specifically the right coronary cusp and part of the left coronary cusp, is the posterior muscular infundibular portion of the RVOT.

Although IdioVAs occur in patients with no structural heart disease, several groups reported that CMR imaging detected structural abnormalities in patients with IdioVAs, which are similar to those seen in the early stages of ARVC/D. CMR showed subtle areas of diminished wall motion and suggested that mild structural abnormalities may be present.⁴⁰⁻⁴³ These findings made the differentiation of ARVC/D and RVOT tachycardia at the time of initial diagnosis more difficult in some patients. In clinical routine CMR imaging is of fundamental value in the diagnosis of ARVC/D; however, a suspicion of ARVC/D cannot be confirmed or excluded based on CMR imaging alone.

On the other hand, it is well established that the typical morphological features of ARVC/D are RV dilatation and/or dysfunction, wall motion abnormalities, diastolic bulging, wall thinning, reduced systolic thickening and trabecular disarray.⁴⁴ Moreover, CMR has the unique ability to detect diffuse or segmental replacement of myocardium in the RV free wall by fibro-fatty tissue.⁴⁵ Delayed enhancement (DE) CMR is effective in detecting the presence, location, and extent of myocardial scarring. DE has been described in areas of fibro-fatty myocardial changes in patients with ARVC/D.⁴⁶ Tandri et al.⁴⁷ first reported an excellent correlation between DE and histopathological diagnosis of fibro-fatty infiltration in patients with ARVC/D. Moreover, they showed that the presence of RV DE was predictive of inducible VT during electrophysiological study. Another group reported DE in 88% of patients studied with

ARVC/D; DE predominantly involved the RV free wall but also affected the RV side of the ventricular septum and, in most of the patients, it was associated with regional contraction abnormality.⁴⁸ A significant inter-observer variability in the interpretation of qualitative findings and segmental contraction analysis of the RV free wall was reported: CMR was implicated in the overdiagnosis of ARVC/D based on the low specificity of qualitative findings, such as increased intramyocardial fat and wall thinning.⁴⁹ A CMR study demonstrated a 93.1% prevalence of RV wall motion abnormalities in healthy subjects, including areas of apparent dyskinesia (75.9%) and bulging (27.6%).⁵⁰ These data indicate that conventional CMR may lead to misdiagnosis of ARVC/D by showing equivocal morphofunctional RV abnormalities. Noteworthy, even if CMR is considered an important test for ARVC/D diagnosis may not detect the initial phases of the disease.

The Adjunctive Role Of Three-Dimensional Electroanatomical Voltage Mapping

Three-dimensional electroanatomical voltage mapping (3D-EAVM) using CARTO system (Biosense-Webster, Diamond Bar, CA, USA) is able to unmask subtle structural heart disease in patients with VAs and an apparently normal heart, despite a thorough noninvasive evaluation, including CMR.⁵¹ Specifically, 3D-EAVM accurately identifies and characterizes low-voltage regions (“electroanatomical scar”) that, in patients with ARVC/D, correspond to areas of myocardial depletion and correlate with



Figure 2: Electroanatomical endocardial 3D mapping shows a large diseased area in the antero-septal portion of the RVOT (<0.5 mV), where fragmented low-voltage electrograms are detected (Panel A, left and right), diagnostic of arrhythmogenic right ventricular cardiomyopathy/dysplasia. VT 12-lead ECG (Panel B) and intracardiac electrograms (Panel C) are shown: radiofrequency delivery at the site of interest, where a diastolic fragmented activity is recorded, immediately terminates the VT.

the histopathological finding of myocardial atrophy and fibro-fatty replacement confirmed at endomyocardial biopsy (EMB).⁵²⁻⁵⁵ Boulos et al.⁵⁶ compared electroanatomical findings in patients with an ultimate diagnosis of IdioVAs with those in patients who had established ARVC/D. They found that mapping results were in concordance with previous clinical diagnosis, by showing normal voltages in the IdioVAs group and abnormal low-amplitude areas

in ARVC/D patients.⁵⁶ These results were however not confirmed by the histopathological study.⁵⁶ Differently, Corrado et al.⁵⁷ demonstrated that some patients with RVOT VT in the absence of RV dilatation and/or dysfunction showed electroanatomical scar in the RVOT corresponding to histopathological features diagnostic of early ARVC/D, like fibro-fatty myocardial replacement, conditioning malignant arrhythmic course. This was consistent with the current perspective on the ARVC/D natural history, and with an early “concealed” phase with subtle RV structural changes that can be identified by 3D-EAVM with a high degree of sensitivity of 100% and specificity of 95%.⁵⁷ Santangeli et al.⁵⁸ compared CMR with 3D-EAVM for scar identification in patients with RV arrhythmias and structural heart disease evidenced at EMB, confirming that 3D-EAVM is more sensitive than DE-CMR, particularly in cases of small scars, and should be used as mapping guide for EMB. Their conclusion was that 3D-EAVM with EMB should be considered when the clinical suspicion is high, because absence of DE does not reliably rule out abnormal myocardial substrates.⁵⁸

Recently, Perazzolo Marra and co-workers confirmed that currently available DE-CMR visualizes RV scars unsatisfactorily: based on their findings, it seems that DE-CMR and 3D-EAVM should not be considered alternative imaging tools in ARVC/D patients, but they should be used synergistically to combine their strategic diagnostic and prognostic information regarding quantitative evaluation of RV function and assessment of arrhythmogenic myocardial substrate.⁵⁹ A new technique to predict the presence and extension of epicardial involvement in patients with ARVC/D undergoing endocardial EAVM was proposed by the Marchlinski’s group. This technique shows that, in patients with limited endocardial substrate, endocardial unipolar intracardiac electrograms (EGMs) <5.5 mV well correlate with electrogram abnormalities detected from the epicardial aspect in patients with ARVC/D;⁶¹ therefore endocardial unipolar electrogram abnormalities may represent the clue of an early “epicardial” disease, that requires further investigation (figure 3).

Radiofrequency Catheter Ablation In IdioVAs And ARVC/D

RFCA of IdioVAs arising from the RVOT is based on two main methods of mapping: activation mapping and pace-mapping. In addition, both available 3D-EAVM systems, CARTOTM (Biosense-Webster, Diamond Bar, CA, USA) or NavXTM (St. Jude Medical, St. Paul, MN, USA), are widely used to relate the anatomy to the mapping data (figure 4, panel A). During activation mapping, the earliest intracardiac bipolar electrogram recorded from the mapping catheter is compared with the surface QRS onset, with an expected advance of 20 to 40 milliseconds (figure 4, panel B-C); a sharp “QS” deflection at the unipolar recording should confirm the site of origin of the arrhythmia. Of note, unipolar EGMs have been related to a high sensitivity for successful ablation sites, but may also be recorded at unsuccessful sites up to 11 mm from the site of origin.^{26,62-64} Pacemapping has been proposed to confirm the activation mapping findings and in particular if PVCs are not frequent or VT is not inducible. It should be performed using as little current as needed to reliably capture and at the same cycle length of VT or similar, and perfect match on a 12-lead ECG with regard to spontaneous arrhythmias is mandatory.⁶⁵⁻⁶⁷

Accordingly to the available published data in respect of the outcome of RFCA for IdioVAs, acute procedural success was reported in 93% of patients, with about 5% of recurrence risk.⁶⁸




Figure 3:

Electroanatomical bipolar endocardial mapping (left anterior oblique, LAO) and right anterior oblique, RAO) views, Panel A and B) is characterized by normal voltage electrograms in the entire right ventricular chamber. Unipolar electrogram analysis shows however in the anterior aspect of the ventricle/RVOT a narrow area where abnormal electrograms (red; $<5.5\text{mV}$) are recorded; this evidence suggests epicardial substrate abnormalities as an initial stage of the disease, that are confirmed by direct epicardial bipolar mapping ($<1.0\text{mV}$).

Serious complications were described in approximately 1% of patients, primarily related to myocardial perforation. For this reason, the integration with the new available technologies, such as contact force information, is mandatory to reduce the risk of perforation

mostly due to the relatively thin structure of the RVOT.¹⁶

RFCA of VAs in ARVC/D patients is not considered curative and thus is not a first-line therapy.¹³⁻¹⁵ The results of RFCA in the setting of ARVC/D-related VAs substantially vary among the several single-




Figure 4: Electroanatomical endocardial 3D mapping (2 projections of the right ventricle) shows normal electrograms confirming the idiopathic nature of the arrhythmia (Panel A). The 3D shell is used for navigation to precisely define earliest ventricular activation that is the target area for radiofrequency delivery (red dots). Intracardiac recording at the site of ablation shows an early presystolic electrogram (Panel B), where radiofrequency delivery instantaneously terminates the VT (exit block is shown) (Panel B and C).

center experiences, reflecting different procedural strategies and mapping techniques. No VT recurrences were reported in 89% of patients treated by the Marchlinski's group during a 27 ± 22 months of follow-up.⁵³ Differently, Verma et al.⁵⁵ achieved a short-term success in 82% of patients, with a VT recurrence at 1, 2, and 3 years of follow-up in 23%, 27%, and 47% of cases, respectively. Also Dalal et al.¹⁴ reported unsatisfactory VT recurrence-free survival rates at 1.5, 5 and 14 months in 75%, 50% and 25% of patients, respectively.¹⁴ Noteworthy, only an endocardial approach was used in most of the

papers published.^{13,14,53,55,69-71} These unsatisfactory results achieved with RFCA may be related to an inadequate characterization of the substrate. Considering the diffuse substrate of ARVC/D and the predominant epicardial involvement and taking into account the relevant incidence of failure using an endocardial-only approach, Garcia et al.⁶⁰ described the role of a combined endo-epicardial substrate-based ablation approach to improve the outcomes in ARVC/D patient population. In this study the feasibility of endo-epicardial substrate-based approach to improve arrhythmia control was demonstrated, underlying importance of targeting the epicardium to further optimize long-term clinical outcome.⁶⁰ During a mean follow-up of 18 ± 12 months from RFCA, 77% of patients have no VT recurrence.⁶⁰ Bai and coworkers⁷² interestingly suggested that the endo-epicardial approach not only increased long-term arrhythmia-free survival but was more likely to result in discontinuation of antiarrhythmic drugs. Berruezo et al.⁷³ showed that a combined endo-epicardial mapping reveals larger epicardial substrate in patients with ARVC/D, confirming the low efficacy of the endocardial-only strategy. Moreover, it was demonstrated that using the endo-epicardial approach including scar dechannelling technique is possible to achieve a high acute success rate with low incidence of recurrence during follow-up.⁷³

RFCA results in a significant reduction in the VT burden among patients with ARVC/D, regardless of ablation strategy. However, despite the better results using the epicardial approach, recurrence rates remain considerable as shown by Philips et al.⁷⁴ In their series of 87 ARVC/D patients undergoing RFCA, they reported a cumulative freedom from VT after epicardial ablation of 64% and 45% at 1 and 5 years, which was significantly longer than with the endocardial approach.⁷⁴

Conclusion

IdioVAs and ARVC/D, even at the early stage, are fundamentally different entities. Nevertheless, clinical presentation is not unequivocal, so that, particularly in early stage of ARVC/D, non-invasive diagnostic tools may direct towards one or the other suspected diagnosis. ECG differences in sinus rhythm between IdioVAs and early stage ARVC/D may be unremarkable, whilst, during VAs different ECG and intracardiac findings have been identified to assist in the differential diagnosis. Currently available imaging techniques are of fundamental importance to recognize RV structural and functional abnormalities and the combined information derived from CMR and 3D-EAVM represent the most effective tool for the identification of myocardial abnormalities in early stages of the disease. The role of RFCA is well established in the setting of IdioVAs, whilst more and more evidences support the use of a combined endo-epicardial substrate-based approach to effectively control the arrhythmic burden in ARVD patients, modifying the course of the disease in a prognostic way.

References

1. Baxton AE, Waxman HL, Marchlinski FE, Simson MB, Cassidy D, Josephson ME. Right ventricular tachycardia: clinical and electro-physiologic characteristics. *Circulation* 1983;68:917-27.
2. Lerman BB, Stein K, Engelstein ED, Battleman DS, Lippman N, Bei D, Catanzaro D. Mechanism of repetitive monomorphic ventricular tachycardia. *Circulation* 1995;92:421-429.
3. Lemery R, Brugada P, Bella PD, Dugernier T, van den Dool A, Wellens HJ. Nonischemic ventricular tachycardia. Clinical course and long-term follow-up in

- patients without clinically overt heart disease. *Circulation* 1989 May;79(5):990-9.
4. Goy JJ, Tauxe F, Fromer M, Schläpfer J, Vogt P, Kappenberger L. Ten-years follow-up of 20 patients with idiopathic ventricular tachycardia. *Pacing Clin Electrophysiol* 1990 Sep;13(9):1142-7.
 5. Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. *N Engl J Med* 1988;318:129-33.
 6. Basso C, Corrado D, Marcus FI, Nava A, Thiene G. Arrhythmogenic right ventricular cardiomyopathy. *Lancet* 2009;373:1289-1300.
 7. Basso C, Thiene G, Corrado D, Angelini A, Nava A, Valente M. Arrhythmogenic right ventricular cardiomyopathy: dysplasia, dystrophy or myocarditis? *Circulation* 1996;94:983-91.
 8. Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, Grosgeat Y. Right ventricular dysplasia: a report of 24 adult cases. *Circulation* 1982;65:384-398.
 9. Corrado D, Basso C, Thiene G, McKenna WJ, Davies MJ, Fontaliran F, Nava A, Silvestri F, Blomstrom-Lundqvist C, Wlodarska EK, Fontaine G, Camerini F. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/ dysplasia: a multicenter study. *J Am Coll Cardiol* 1997;30:1512-20.
 10. Basso C, Corrado D, Baucé B, Thiene G. Arrhythmogenic Right Ventricular Cardiomyopathy. *Circ Arrhythm Electrophysiol* 2012;5:1233-1246.
 11. Sen-Chowdhry S, Syrris P, Ward D, Asimaki A, Sevdalis E, McKenna WJ. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. *Circulation* 2007;115:1710-1720.
 12. Marcus FI, McKenna WJ, Sherrill D, Basso C, Baucé B, Bluemke DA, Calkins H, Corrado D, Cox MG, Daubert JP, Fontaine G, Gear K, Hauer R, Nava A, Picard MH, Protonotarios N, Saffitz JE, Yoerger Sanborn DM, Steinberg JS, Tandri H, Thiene G, Towbin JA, Tsatsopoulou A, Witcher T, Zareba W. Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Proposed Modification of the Task Force Criteria. *Circulation* 2010;121:1533-1541.
 13. Aliot EM, Stevenson WG, Almendral-Garrote JM, Bogun F, Calkins CH, Delacretaz E, Della Bella P, Hindricks G, Jais P, Josephson ME, Kautzner J, Kay GN, Kuck KH, Lerman BB, Marchlinski F, Reddy V, Schalij MJ, Schilling R, Soejima K, Wilber D. EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). *Europace* 2009; 11(6): 771-817.
 14. Dalal D, Jain R, Tandri H, Dong J, Eid SM, Prakasa K, Tichnell C, James C, Abraham T, Russell SD, Sinha S, Judge DP, Bluemke DA, Marine JE, Calkins H. Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/ cardiomyopathy. *J Am Coll Cardiol* 2007;50:432-440.
 15. Arbelo E, Josephson ME. Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia. *J Cardiovasc Electrophysiol* 2010; 21:473-486.
 16. Asirvatham MJ. Correlative Anatomy for the Invasive Electrophysiologist: Outflow Tract and Supralvar Arrhythmia. *J Cardiovasc Electrophysiol* 2009;20:955-968.
 17. de Jong F, Opthof T, Wilde AA, Janse MJ, Charles R, Lamers WH, Moorman AF. Persisting zones of slow impulse conduction in developing chicken hearts. *Circ Res* 1992 Aug;71(2):240-50.
 18. Jongbloed MR, Mahtab EA, Blom NA, Schalij MJ, Gittenberger-De Groot AC. Development of the cardiac conduction system and the possible relation to predilection sites of arrhythmogenesis. *Scientific World Journal* 2008 Mar 3;8:239-69.
 19. Vicente-Steijn R, Passier R, Wisse LJ, Schalij MJ, Poelmann RE, Gittenberger-De Groot AC, Jongbloed MR. Funny current channel HCN4 delineates the developing cardiac conduction system in chicken heart. *Heart Rhythm* 2011;8(8):1254-63.
 20. Jongbloed MR, Schalij MJ, Poelmann RE, Blom NA, Fekkes ML, Wang Z, Fishman GI, Gittenberger-De Groot AC. Embryonic conduction tissue: a spatial correlation with adult arrhythmogenic areas. *J Cardiovasc Electrophysiol* 2004;15(3):349-355.
 21. Kondo RP, Anderson RH, Kupersmidt S, Roden DM, Evans SM. Development of the cardiac conduction system as delineated by minK-lacZ. *J Cardiovasc Electrophysiol* 2003;14:383-91.
 22. Calvo N, Jongbloed MR, Zeppenfeld K. Radiofrequency catheter ablation of idiopathic right ventricular outflow tract arrhythmias. *Indian Pacing Electrophysiol J* 2013;13(1):14-33.
 23. Thiene G, Nava A, Angelini A, Daliento L, Scognamiglio R, Corrado D. Anatomical aspects of arrhythmogenic right ventricular cardiomyopathy. In *Advances in cardiomyopathies*. Baroldi G, Camerini F, Goodwin JF, eds. Milano: Springer Verlag; 1990:397-408.
 24. McKenna WJ, Thiene G, Nava A, Fontaliran F, Blomstrom-Lundqvist C, Fontaine G, Camerini F. Diagnosis of arrhythmogenic right ventricular dysplasia/ cardiomyopathy. Task Force of the Working Group on Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. *Br Heart J* 1994; 71: 215-218.
 25. Turrini P, Corrado D, Basso C, Nava A, Baucé B, Thiene G. Dispersion of ventricular depolarization-repolarization: a noninvasive marker for risk stratification in arrhythmogenic right ventricular cardiomyopathy. *Circulation* 2001;103: 3075-3080.
 26. Fontaine G, Fontaliran F, Hebert JL, Chemla D, Zenati O, Lecarpentier Y, Frank R. Arrhythmogenic right ventricular dysplasia. *Annu Rev Med* 1999; 50: 17-35.
 27. Peters S, Trummel M. Diagnosis of arrhythmogenic right ventricular dysplasia-cardiomyopathy: value of standard ECG revisited. *Ann Noninvasive Electrocardiol* 2003; 8: 238-245.
 28. Nasir K, Bomma C, Tandri H, Roguin A, Dalal D, Prakasa K, Tichnell C, James C, Spevak PJ, Marcus F, Calkins H. Electrocardiographic features of arrhythmogenic right ventricular dysplasia/cardiomyopathy according to disease severity: a need to broaden diagnostic criteria. *Circulation* 2004;110:1527-1534.
 29. Migliore F, Zorzi A, Michieli P, Perazzolo Marra M, Siciliano M, Rigato I, Baucé B, Basso C, Toazza D, Schiavon M, Iliceto S, Thiene G, Corrado D. Prevalence of cardiomyopathy in Italian asymptomatic children with electrocardiographic T-wave inversion at preparticipation screening. *Circulation* 2012;125:529-538.
 30. Niroomand F, Carbuicchio C, Tondo C, Riva S, Fassini G, Apostolo A, Trevisi N, Della Bella P. Electrophysiological characteristics and outcome in patients with idiopathic right ventricular arrhythmia compared with arrhythmogenic right ventricular dysplasia. *Heart* 2002;87:41-47.
 31. Hoffmayer KS, Machado ON, Marcus GM, Yang Y, Johnson CJ, Ermakov S, Vittinghoff E, Pandurangi U, Calkins H, Cannom D, Gear KG, Tichnell C, Park Y, Zareba W, Marcus FI, Scheinman MM. Electrocardiographic comparison of ventricular arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy and right ventricular outflow tract tachycardia. *J Am Coll Cardiol* 2011;58(8):831-8.
 32. Dixit S, Gerstenfeld EP, Callans DJ, Marchlinski FE. Electrocardiographic patterns of superior right ventricular outflow tract tachycardias: distinguishing septal and free-wall sites of origin. *J Cardiovasc Electrophysiol* 2003;14:1-7.
 33. Huang SKS, Wood MA. Ablation of ventricular outflow tract tachycardia. In: Huang SKS, Wood MA. *Catheter ablation of cardiac arrhythmias*. 2 ed. Philadelphia, PA: Saunders Elsevier, 2011:446-462.
 34. O'Donnell D, Cox D, Bourke J, Mitchell L, Furniss S. Clinical and electrophysiological differences between patients with arrhythmogenic right

- ventricular dysplasia and right ventricular outflow tract tachycardia. *Eur Heart J* 2003;24:801-810.
35. Yodogawa K, Morita N, Kobayashi Y, Takayama H, Ohara T, Seino Y, Katoh T, Mizuno K. A new approach for the comparison of conduction abnormality between arrhythmogenic right ventricular cardiomyopathy/dysplasia and Brugada syndrome. *Ann Noninvasive Electrocardiol*. 2011;16:263-9.
 36. Lerman BB, Belardinelli L, West GA, Berne RM, Di Marco JP. Adenosine-sensitive ventricular tachycardia: evidence suggesting cyclic AMP-mediated triggered activity. *Circulation* 1986;74:270-80.
 37. Peters NS, Cabo C, Witt AL. Arrhythmogenic mechanisms: automaticity, triggered activity and reentry. In: Zipes DP, Jalife J, editors. *Cardiac electrophysiology: from cell to bedside*. WB Saunders: Philadelphia; 2000, p. 345-56.
 38. Josephson ME, Horowitz LN, Farshidi A, Spielman SR, Michelson EL, Greenspan AM. Sustained ventricular tachycardia: evidence for protected localized reentry. *Am J Cardiol* 1978;42:416-24.
 39. Ellison KE, Friedman PL, Ganz LI, Stevenson WG. Entrainment mapping and radiofrequency catheter ablation of ventricular tachycardia in right ventricular dysplasia. *J Am Coll Cardiol* 1988;32:724-728.
 40. Carlson MD, White RD, Trohman RG, Adler LP, Biblo LA, Merkatz KA, Waldo AL. Right ventricular outflow tract tachycardia: detection of previously unrecognized anatomic abnormalities using cine magnetic resonance imaging. *J Am Coll Cardiol* 1994;24:720-7.
 41. White RD, Trohman RG, Flamm SD, VanDyke CW, Optican RJ, Sterba R, Obuchowski NA, Carlson MD, Tchou PJ. Right ventricular arrhythmia in the absence of arrhythmogenic dysplasia: MR imaging of myocardial abnormalities. *Radiology* 1998;207:743-751.
 42. Globits S, Kreiner G, Frank H, Heinz G, Klaar U, Frey B, Gössinger H. Significance of morphological abnormalities detected by MRI in patients undergoing successful ablation of right ventricular outflow tract tachycardia. *Circulation* 1997;96:2633-2640.
 43. Markowitz SM, Litvak BL, Ramirez de Arellano EA, Markisz JA, Stein KM, Lerman BB. Adenosine sensitive ventricular tachycardia: Right ventricular abnormalities delineated by magnetic resonance imaging. *Circulation* 1997;96:1192-2000.
 44. Tandri H, Calkins H, Nasir K, Bomma C, Castillo E, Rutberg J, Tichnell C, Lima JAC, Bluemke DA. Magnetic resonance imaging findings in patients meeting task force criteria for arrhythmogenic right ventricular dysplasia. *J Cardiovasc Electrophysiol* 2003;14:476-482.
 45. Ricci C, Longo R, Pagnan L, Dalla Palma L, Pinamonti B, Camerini F, Bussani R, Silvestri F. Magnetic resonance imaging in right ventricular dysplasia. *Am J Cardiol* 1992;70:1589-1595.
 46. Bluemke DA, Krupinski EA, Ovitt T, Gear K, Unger E, Axel L, Boxt LM, Casolo G, Ferrari VA, Funaki B, Globits S, Higgins CB, Julsrud P, Lipton M, Mawson J, Nygren A, Pennell DJ, Stillman A, White RD, Wichter T, Marcus F. MR Imaging of arrhythmogenic right ventricular cardiomyopathy: morphologic findings and interobserver reliability. *Cardiology* 2003;99:153-162.
 47. Tandri H, Saranathan M, Rodriguez ER, Martinez C, Bomma C, Nasir K, Rosen B, Lima JA, Calkins H, Bluemke DA. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. *J Am Coll Cardiol* 2005;45(1):98-103.
 48. Pfluger HB, Phrommintikul A, Mariani JA, Cherayath JG, Taylor AJ. Utility of myocardial fibrosis and fatty infiltration detected by cardiac magnetic resonance imaging in the diagnosis of arrhythmogenic right ventricular dysplasia—a single centre experience. *Heart Lung Circ* 2008;17(6):478-483.
 49. Tandri H, Castillo E, Ferrari VA, Nasir K, Dalal D, Bomma C, Calkins H, Bluemke DA. Magnetic resonance imaging of arrhythmogenic right ventricular dysplasia: sensitivity, specificity, and observer variability of fat detection versus functional analysis of the right ventricle. *J Am Coll Cardiol* 2006;48:2277-2284.
 50. Sievers B, Addo M, Franken U, Trappe HJ. Right ventricular wall motion abnormalities found in healthy subjects by cardiovascular magnetic resonance imaging and characterized with a new segmental model. *J Cardiovasc Magn Reson*. 2004;6:601-608.
 51. Dello Russo A, Pieroni M, Santangeli P, Bartoletti S, Casella M, Pelargonio G, Smaldone C, Bianco M, Di Biase L, Bellocci F, Zeppilli P, Fiorentini C, Natale A, Tondo C. Concealed cardiomyopathies in competitive athletes with ventricular arrhythmias and an apparently normal heart: role of cardiac electroanatomical mapping and biopsy. *Heart Rhythm* 2011;8:1915-1922.
 52. Boulos M, Lashevsky I, Reisner S, Gepstein L. Electroanatomical mapping of arrhythmogenic right ventricular dysplasia. *J Am Coll Cardiol* 2001;38:2020-7.
 53. Marchlinski FE, Zado E, Dixit S, Gerstenfeld E, Callans DJ, Hsia H, Lin D, Nayak H, Russo A, Pulliam W. Electroanatomic substrate and outcome of catheter ablation therapy for ventricular tachycardia in setting of right ventricular cardiomyopathy. *Circulation* 2004;110:22930-8.
 54. Corrado D, Basso C, Leoni L, Tokajuk B, Bauce B, Frigo G, Tarantini G, Napodano M, Turrini P, Ramondo A, Daliento L, Nava A, Buja G, Iliceto S, Thiene G. Three-dimensional electroanatomic voltage mapping increases accuracy of diagnosing arrhythmogenic right ventricular cardiomyopathy/dysplasia. *Circulation* 2005;111:3042-50.
 55. Verma A, Kilicaslan F, Schweikert RA, Tomassoni G, Rossillo A, Marrouche NF, Ozduran V, Wazni OM, Elayi SC, Saenz LC, Minor S, Cummings JE, Burkhardt JD, Hao S, Beheiry S, Tchou PJ, Natale A. Short- and long-term success of substrate-based mapping and ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia. *Circulation* 2005;111:3209-16.
 56. Boulos M, Lashevsky I, Gepstein L. Usefulness of electroanatomical mapping to differentiate between right ventricular outflow tract tachycardia and arrhythmogenic right ventricular dysplasia. *Am J Cardiol* 2005;95:935-40.
 57. Corrado D, Basso C, Leoni L, Tokajuk B, Turrini P, Bauce B, Migliore F, Pavei A, Tarantini G, Napodano M, Ramondo A, Buja G, Iliceto S, Thiene G. Three-Dimensional electroanatomical voltage mapping and histologic evaluation of myocardial substrate in right ventricular outflow tract tachycardia. *J Am Coll Cardiol* 2008;51:731-740.
 58. Santangeli P, Hamilton-Craig C, Dello Russo A, Pieroni M, Casella M, Pelargonio G, Di Biase L, Smaldone C, Bartoletti S, Narducci ML, Tondo C, Bellocci F, Natale A. Imaging of scar in patients with ventricular arrhythmias of right ventricular origin: cardiac magnetic resonance versus electroanatomic mapping. *J Cardiovasc Electrophysiol* 2011;22:1359-1366.
 59. Perazzolo Marra M, Leoni L, Bauce B, Corbetti F, Zorzi A, Migliore F, Silvano M, Rigato I, Tona F, Tarantini G, Cacciavillani L, Basso C, Buja G, Thiene G, Iliceto S, Corrado D. Imaging study of ventricular scar in arrhythmogenic right ventricular cardiomyopathy. Comparison of 3D standard electroanatomical voltage mapping and contrast-enhanced cardiac magnetic resonance. *Circ Arrhythmia Electrophysiol* 2012;5:91-100.
 60. Garcia FC, Bazan V, Zado ES, Ren JF, Marchlinski FE. Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in the arrhythmogenic right ventricular cardiomyopathy/dysplasia. *Circulation* 2009;120:366-375.
 61. Polin GM, Haqqani H, Tzou W, Hutchinson MD, Garcia FC, Callans DJ, Zado ES, Marchlinski FE. Endocardial unipolar voltage mapping to identify epicardial substrate in arrhythmogenic right ventricular cardiomyopathy/dysplasia. *Heart Rhythm* 2011;8(1):76-83.
 62. Azegami K, Wilber DJ, Arruda M, Lin AC, Denman RA. Spatial resolution of pacemapping and activation mapping in patients with idiopathic right ventricular outflow tract tachycardia. *J Cardiovasc Electrophysiol* 2005;16:823-9.
 63. Miller JM, Pezeshkian NG, Yadav AV. Catheter mapping and ablation of right ventricular outflow tract ventricular tachycardia. *J Cardiovasc Electrophysiol* 2006;17:800-2.
 64. Merino JL, Jimenez-Borreguero J, Peinado R, Merino SV, Sobrino JA. Unipolar

- mapping and magnetic resonance imaging of “idiopathic” right ventricular outflow tract ectopy. *J Cardiovasc Electrophysiol* 1998;9:84-87.
65. Stevenson WG, Soejima K. Recording techniques for clinical electrophysiology. *J Cardiovasc Electrophysiol* 2005; 16: 1017-22.63.
66. Goyal R, Harvey M, Daoud EG, Brinkman K, Knight BP, Bahu M, Weiss R, Bogun F, Man KC, Strickberger SA, Morady F. Effect of coupling interval and pacing cycle length on morphology of paced ventricular complexes. Implications for pace mapping. *Circulation* 1996; 94: 2843-9.
67. Gerstenfeld EP, Dixit S, Callans DJ, Rajawat Y, Rho R, Marchlinski FE. Quantitative comparison of spontaneous and paced 12-lead electrocardiogram during right ventricular outflow tract ventricular tachycardia. *J Am Coll Cardiol* 2003; 41: 2046-53.
68. Joshi S, Wilber DJ. Ablation of idiopathic right ventricular outflow tract tachycardia: current perspectives. *J Cardiovasc Electrophysiol* 2005;16:S52-S58.
69. Satomi K, Kurita T, Suyama K, Noda T, Okamura H, Otomo K, Shimizu W, Aihara N, Kamakura S. Catheter ablation of stable and unstable ventricular tachycardias in patients with arrhythmogenic right ventricular dysplasia. *J Cardiovasc Electrophysiol* 2006;17:469-476.
70. Wijnmaalen AP, Schalijs MJ, Bootsma M, Kies P, DE Roos A, Putter H, Bax JJ, Zeppenfeld K. Patients with scar-related right ventricular tachycardia: determinants of long-term outcome. *J Cardiovasc Electrophysiol*. 2009;20:1119-1127.
71. Milhoen H, State S, de Chillou C, Magnin-Poull I, Dotto P, Andronache M, Abdelaal A, Aliot E. Electroanatomic mapping characteristics of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. *Europace* 2005;7:516-524.
72. Bai R, Di Biase L, Shivkumr K, Mohanty P, Tung R, Santangeli P, Saenz LC, Vacca M, Verma A, Khaykin Y, Mohanty S, Burkhardt JD, Hongo R, Beheiry S, Dello Russo A, Casella M, Pelargonio G, Santarelli P, Sanchez J, Tondo C, Natale A. Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy: arrhythmia-free survival after endo-epicardial substrate based mapping and ablation. *Circ Arrhythm Electrophysiol* 2011;4:478-485.
73. Berruezo A, Fernandez-Armenta J, Mont L, Zeljko H, Andreu D, Herczku C, Boussy T, Tolosana JM, Arbelo E, Brugada J. Combined endocardial and epicardial catheter ablation in arrhythmogenic right ventricular dysplasia incorporating scar dechanneling technique. *Circ Arrhythm Electrophysiol* 2012;5:111-121.
74. Philips B, Madhavan S, James C, Tichnell C, Murray B, Dalal D, Bhonsale A, Nazarian S, Judge DP, Russell SD, Abraham T, Calkins H, Tandri H. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Circ Arrhythm Electrophysiol* 2012;5:499-505.